Show notes
Chuck Drake and Doug Johnson discuss possible risk benefits of immune checkpoint inhibitors during the COVID-19 pandemic.
Chuck Drake and Doug Johnson discuss possible risk benefits of immune checkpoint inhibitors during the COVID-19 pandemic.